List view / Grid view
Following on from the first GMP registration of a cannabis API for a UK pharmaceutical facility, EPR spoke with Celadon Pharmaceuticals about how it navigated the complex regulatory landscape.
FDA researchers found there was some reduction in microbial counts by heating cannabis with a commercial vaporiser to limit microbial contamination, but they were not statistically significant.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK manufacturing facility good manufacturing practice (GMP) registration for its cannabis API.
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than any other medication, including opioids.
In this article, EPR summarises the list of 10 recommendations for the UK Government, published by experts in the medicinal cannabis industry, to ensure the UK capitalises on the opportunities afforded by the market.
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
Sarah Ellson from Fieldfisher spoke with European Pharmaceutical Review to discuss the position of medicinal cannabis in the UK and the impacts of Brexit.
European Pharmaceutical Review spoke with Dean Petkanas from Neuropathix, formerly known as Kannalife, to find out why a CBD-inspired molecule can offer an improved therapeutic value.
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
European Pharmaceutical Review spoke with Dr Andy Yates to discuss Artelo Bioscience’s new CBD and TMP cocrystal, with the potential to treat PTSD.
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
A new study has shown that in children and adolescents with an intellectual disability, cannabidiol (CBD) reduced severe behavioural problems.
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
